IMPORTANCE Amyotrophic lateral sclerosis (ALS) is a common adult-onset neurodegenerative disease characterized by selective loss of upper and lower motor neurons. Patients with ALS have persistent peripheral and central inflammatory responses including abnormally functioning T cells and activated microglia. However, much less is known about the inflammatory gene profile of circulating innate immune monocytes in these patients.
A myotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease. At sites of motor neuron injury in the central nervous system (CNS), neuroinflammation is a prominent pathological finding in autopsy tissues that is characterized by microglial activation and perivascular infiltration of monocytes and T cells.
1 Positron emission tomographic images of brains from living patients with ALS demonstrate widespread microglial activation. Moreover, increased microglial activation in these patients' motor cortices correlates with the severity of upper motor neuron clinical signs.
2,3
Similar results have been obtained from mutant superoxide dismutase (mSOD1) transgenic animal models of ALS. Activated microglia were observed before disease onset and increased as disease progressed. 4, 5 Furthermore, replacing mSOD1 CNS microglia with wild-type microglia or removing mSOD1 from microglia prolonged survival of ALS mice. [6] [7] [8] These data suggest that microglia play an active role in motor neuron degeneration of patients with ALS as well as transgenic mice. Because monocytes are the peripheral blood homologue of CNS microglia, these data raise the question as to whether monocytes similarly contribute to ALS pathology. Because direct sampling of microglia from patients with ALS is not feasible, peripheral monocyte/macrophages may provide evidence of systemic innate immune system activation in patients. In this study, using high-throughput unbiased deep RNA sequencing (RNA-seq), we sought to demonstrate that ALS monocytes are skewed toward a proinflammatory state in the peripheral circulation and determine whether they represent a potential target for disease modification.
Methods

Participants
This study was approved by the Houston Methodist Hospital institutional review board. All patients and healthy control individuals signed informed consent before peripheral blood samples were drawn. Patients were seen at the Muscular Dystrophy Association/ALS Clinic at Houston Methodist Hospital Neurological Institute (Houston, Texas) and evaluated for functional status using the Appel ALS (AALS) score (range, 30-164) 9,10 as well as the revised ALS Functional Rating Scale.
None of the patients and healthy control individuals had evidence of ongoing infectious/inflammatory diseases. Progression rate was determined as the change of AALS score from the initial clinical visit to the collection time. Rapidly progressing patients were defined as those progressing at a rate of greater than or equal to 1.5 AALS points/month, and slowly progressing patients were defined as those progressing at a rate of less than 1.5 AALS points/month. 11 The demographics between the patients with ALS (mean [SD] age, 58.8 [1.57] years; 55.8% were men and 44.2% were women; and 90.7% were white, 4.65% were Hispanic, 2.33% were black, and 2.33% were Asian) and control individuals were similar (mean [SD] age, 57.6 [2.15] years; 50.0% were men and 50.0% were women; and 90.9% were white, none were Hispanic, none were black, and 9.09% were Asian).
Monocyte Isolation
Human monocytes were freshly isolated from peripheral blood of 43 patients with ALS and 22 healthy control individuals. According to the manufacturer's instructions, human Pan Monocyte Isolation Kit (Miltenyi Biotec) was used to obtain monocytes by negative selection. The purity of pan monocytes was 91% to 96% as determined by flow cytometry.
Quantitative Reverse Transcription Polymerase Chain Reaction
RNA was extracted and purified from ex vivo monocytes using Direct-zol RNA MiniPrep Kit (Zymo Research) according to manufacturer's instructions. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed using a 1-step RT-PCR kit with SYBR Green on an iQ5 Multicolor Realtime PCR detection System (Bio-Rad Laboratories). Primers and conditions of PCR were shown in Table 1 . Primer efficiency was assessed by analyzing a serial dilution of RNA. The relative expression level of each mRNA was calculated using the ΔΔCt method normalizing to β-actin and relative to the control samples. The presence of 1 product of the correct size was verified by both 2% agarose gel electrophoresis and melt curve analyses containing a single melt curve peak.
per kilobase of transcript per million mapped reads or reads per kilobase of transcript per million mapped reads; the normalization of DESeq2 is more precise than other normalization methods. 13, 14 DESeq2 analysis is based on the hypothesis that most genes are not differentially expressed; the median of this ratio for each sample provides an estimate of the correction factor that should be applied to all read counts of this sample to fulfill the hypothesis. 14 The function analysis of DEGs was performed using Ingenuity Pathway Analysis (Qiagen).
Enzyme-Linked Immunosorbent Assay
Human interleukin (IL) 8 enzyme-linked immunosorbent assay Ready-SET-Go kit (eBioscience) and Quantikine enzymelinked immunosorbent assay kits for human IL-1β, IL-6, tumor necrosis factor (TNF) α, or interferon (IFN) γ (R&D Systems) were used to determine cytokine concentrations in serum samples of patients with ALS and healthy control individuals according to manufacturer's instructions.
Statistical Analysis
The DEGs between control individuals and patients with ALS were analyzed using analysis of variance for more than 2 groups or t test for 2 groups. Data are expressed as mean (SE), and P less than .05 was considered significant. The P value was 2-sided.
Results
Gene Expression of Monocytes of Patients With ALS
To determine the gene expression profile of ALS monocytes in an unbiased manner, we subjected the first set of monocyte RNA samples from 23 patients with ALS and 10 healthy control individuals to deep RNA-seq. Based on selection criteria of fold change greater than 2, P < .01, and false discovery rate less than 0.25, RNA-seq results revealed 233 DEGs from monocytes of patients with ALS compared with the monocytes of healthy control individuals (eTable 1 in the Supplement). Of these DEGs, Figure 1A shows the top 10 upregulated genes that had the largest differences on medium of gene expression levels between patients with ALS and healthy control individuals. The heat map of these 10 genes showed a distinct expression pattern of monocytes of patients with ALS compared with healthy control individuals' monocytes ( Figure 1B ). Most importantly, except for EIF5 (a GTPaseactivating protein), 9 of these 10 top DEGs, including IL1B, IL8, NAMPT, SLC2A3, FOSB, and CD83, are involved in proinflammatory responses of monocytes.
To validate RNA-seq data, we prepared monocyte RNA samples from additional patients with ALS and healthy control individuals and measured the mRNA level of a proinflammatory cytokine IL-1β by qRT-PCR. As shown in Figure 2A , monocytes of patients with ALS (n = 43; mean [SE], 2.3 [0.30] ) expressed more IL1B message than monocytes isolated from control individuals (n = 22; mean [SE], 1.0 [0.11]; P < .001). Expression of NLRP3,the major component of NLRP3 inflammasome responsible for IL-1β production, was also upregulated in monocytes of patients with ALS (n = 43) compared with control monocytes (n = 22; mean [SE], 1.00 [0.07]; P = .007; Figure 2B ). Furthermore, we chose IL8, FOSB, CD83, SOCS3, CXCL1, and CXCL2 from the inflammationrelated DEGs and assessed their mRNA expression levels by qRT-PCR. Monocytes of patients with ALS (n = 43) had higher IL8, FOSB, CD83, SOCS3, CXCL1,andCXCL2 expression levels than monocytes from healthy control individuals (n = 22, Figure 2C- CD83, 1.00 [0.12]; P = .02; SOCS3, 1.00 [0.16]; P = .01; CXCL1,1.00 [0.14]; P = .002; and CXCL2, 1.00 [0.11]; P= .01). These data confirmed RNA-seq results, indicating that inflammation-associated genes were upregulated in ALS monocytes.
Both qRT-PCR and deep RNA-seq data were generated from pan monocytes by negative selection, which allowed us to obtain untouched pan monocytes. We also performed RNA-seq on monocytes isolated by a positive selection method using CD14 microbeads (Miltenyi Biotec). Principal component analysis indicated that overall RNA messages of negatively selected pan monocyte from patients with ALS were more distinguishable from healthy control individuals than CD14 + ALS monocytes vs CD14 + control monocytes by positive selection (eFigure 1 in the Supplement). CD14 + ALS monocytes exhibited fewer DEGs when compared with control monocytes isolated by the same positive selection method (data not shown).
The attachment of CD14 antibody on monocytes may activate them and influence gene expression of these cells, while pan monocytes by negative selection had no bound antibody. Therefore, data from negatively selected pan monocytes more accurately reflect in vivo features of ALS monocytes than positively selected CD14 + monocytes.
Next, we separated patients with ALS into slowly and rapidly progressing groups, using the AALS score of 1.5 points/ month as a cutoff. This cutoff was defined by accessing the progression rates of more than 4000 patients' records in our database and statistically determining the median progression rate.
11 Using this cutoff, we previously separated 54 patients with ALS surviving less than 2 years after diagnosis from those that survive up to 6 years or more. 11 With our past experience with increased sensitivity of the AALS in early disease progression, AALS was used to stratify slow and fast progression rates. Moreover, using the statistically determined : 5′-TTC GAC ACA TGG GAT AAC GAG G-3′  Reverse: 5′-TTC GAC ACA TGG GAT AAC GAG G-3′   53.8   NLRP3  Forward: 5′-CGT GAG TCC CAT TAA GAT GGA GT-3′  Reverse: 5′-CCC GAC AGT GGA TAT AGA ACA GA-3′   58   IL8  Forward: 5′-AGC TCT GTG TGA AGG TGC AGT-3′  Reverse: 5′-AAT TTC TGT GTT GGC GCA GTG-3′ 55.4
CD83
Forward: 5′-ATG GAG ACA CCC CAG GAA GAC-3′ Reverse: 5′-TCA GGG AAT AGG GCC TTT CA-3′
63.1 FOSB Forward: 5′-AGC AGC AGC TAA ATG CAG GA-3′ Reverse: 5′-TTC GTA GGG GAT CTT GCA GC-3′ score of 1.5 points/month for AALS and 1.0 points/month for the revised ALS functional rating, the revised ALS functional rating scores gave relatively comparable designations as slow or fast rates as the AALS scores in 18 of 22 patients (82%, eTable 2intheSupplement). After comparing RNA-seq data of slow or fast groups with the control group, more DEGs were identified than what was observed with the combined ALS group vs controls. This is because several genes were differentially expressed in opposite directions in slow and fast ALS groups; some genes changed in one ALS group but not in another ALS group when compared with the control group. These analyses demonstrated that 65 DEGs were specifically expressed in monocytes from patients with slowly progressing ALS and 237 DEGs were solely found in monocytes from patients with rapidly progressing ALS; 43 DEGs were expressed in both the slow and fast groups (eFigure 2 and eTables 3-5 in the Supplement). Functional analysis of these DEGs revealed that monocytes from patients with rapidly progressing ALS contained more DEGs that are tightly associated with inflammatory disease or inflammatory functions than monocytes from slowly progressing patients ( Table 2 ; the P values indicate the possibility that these genes are not involved in the corresponding disease or function category). Eighty-four DEGs participated in cell migration and chemotaxis in monocytes of patients with rapidly progressing ALS, while 30 DEGs were involved in migration and chemotaxis in monocytes from patients with slowly progressing ALS. Forty-seven genes encoded molecules acting on the activation of monocytes from rapidly progressing patients, while 22 DEGs were associated with cell activation in monocytes of slowly progressing patients. In addition, 44 monocytic DEGs were closely related with inflammatory responses in rapidly progressing patients, while 19 genes were associated with inflammatory responses in monocytes from slowly progressing patients. These DEGs associated with inflammatory responses were also illustrated in a heat map ( Figure 3 ). These data indicate that ALS monocytes more actively participate in immune responses during fast progression than during slow progression and may contribute to the accelerating progression of ALS.
Peripheral Cytokine Levels
Serum IL-1β, IL-6, TNF-α, and IFN-γ were assayed by enzymelinked immunosorbent assays, but all were at background levels in ALS and control serum samples and were neither repro- 
Discussion
Our deep RNA-seq and qRT-PCR data demonstrated that monocytes isolated from patients with ALS expressed a unique gene profile associated with proinflammatory immune responses. Nine of 10 top upregulated DEGs shown in Figure 1A are involved in inflammation. Seven of these 9 genes are directly involved in proinflammatory pathways, while 2 are involved in the negative feedback resolution of the proinflammatory response. Interleukin 1β is a major inflammatory cytokine produced by activated monocytes/macrophages. Blockade of the IL-1β receptor or an induced IL-1β deficiency resulted in less microglia activation and less motor neuron loss and prolonged survival in ALS mice, indicating that IL-1β participates in ALS progression. 15 Nicotinamide phosphoribosyltransferase (NAMPT), also known as a pre-B-cell colony-enhancing factor, has multiple functions. In a study, 16 silencing NAMPT gene expression in monocytes reduced IL-6 production by these cells, leading to fewer Th17 cells and reduced autoantibody titers as well as decreased infiltration of monocytes/ macrophages and neutrophils in arthritic joints, suggesting the role of monocytic NAMPT in inflammation. 16 FOSB is a key subunit of transcription factor AP-1. Stimulation of adenosine triphosphate receptor P2RX7 led to the induction of FOSB and activation of AP-1 in monocytes; subsequent upregulation of COX-2 indicated FOSB was transcriptionally active in monocytic activation. 17 CD83 has functions of regulating antigen presentation. Upregulation of CD83 and more antigen presentationassociated DEGs (as shown in Table 2 ) in monocytes of patients with rapidly progressing ALS implies that monocytes may engage in presenting antigen during disease progression. SOCS3 and TNFAIP3 are 2 negative regulators of inflammation and immunity. They are induced in activated immune cells and exert their inhibitory function by downregulating overactivated NF-κB and IRF3 pathways and avoid too much proinflammatory gene expression in a negative feedback loop. Their induction in ALS 
, and CXCL2 (H) in monocytes of patients with amyotrophic lateral sclerosis (ALS) (n = 43) were verified by quantitative reverse transcription polymerase chain reaction. Arbitrary unit of each mRNA was normalized to β-actin and relative to the healthy control (HC) samples (n = 22). Error bars indicate the standard error.
a P < .01 vs HC (IL1B, P< .001; NLRP3, P = .007; IL8, P = .002; FOSB, P = .009; and CXCL1, P = .002).
b P < .05 vs HC (CD83, P =.02;SOCS3, P = .01; and CXCL2, P = .01). Proinflammatory cytokines, such as TNF-α, IL-6, and IFN-γ, have been reported to be elevated in plasma or serum samples of patients with ALS, with levels increasing as disease progresses. [21] [22] [23] However, in our studies, IL-6, TNF-α, and IFN-γ protein levels measured by enzyme-linked immunosorbent assay were at background levels in ALS and control serum samples and were neither reproducible nor reliable. Furthermore, IL-1β serum protein levels were not readily detectable, despite definite evidence of IL1B ISG15  MCL1  FCGR3A  PTGS2  IL10  ATF3  GATA3  CH25H  SERPING1  SERPING1  HCAR2  FLT1  RGCC  PIK3R5  CCL2  CCL7  CCL8  MMP28  SOCS3  LGALS3BP  FCAR  IL1B  NR4A2  DPP4  SIGLEC1  NFATC2  NFATC2  ZBP1  OSM  LTF  GNAI2  PTX3  MECOM  CXCL8  CXCL1  CXCL2  CXCL11  NEDD9  TREM1  TNFAIP3  GNA12  AHR  IL6  RABGEF1  PIK3CG  SYK  NFIL3  PTGES  CD40LG   13932  13987  13839  13930  13931  13875  13940  13883  13874  13943  13882  13939  13863  13985  13859  13856  13914  13927  13938  13919  13838  13925  13851  13911  13974  13912  13845  13835  13868  13841  13942  13973 More proinflammatory differentially expressed genes were upregulated in monocytes isolated from patients with rapidly progressing amyotrophic lateral sclerosis (ALS fast, n = 10) than from patients with slowly progressing ALS (ALS slow, n = 12) or control groups (HC, n = 10). RNA expression in both ALS and control monocytes, with increased IL1B mRNA expression in ALS monocytes. This result could be explained either as an extremely short cytokine half-life within plasma or serum samples, following rapid consumption in an autocrine or paracrine manner, or as enhanced secretion only following migration to tissues, including the CNS. Our inability to reproduce inflammatory cytokine serum levels published by others was a major impetus for examining the cell-based RNA expression of such inflammatory cytokines. On repetitive testing, only IL-8 protein levels were increased in serum samples of patients with rapidly progressing disease, but such levels were close to background and were not as definitively increased as IL8 gene expression. Nevertheless, a 2015 study 24 did show that serum IL-8 protein levels increased during disease progression. 24 Additional studies have also reported elevated IL-8 protein cerebrospinal levels in patients with ALS, especially in those patients with lower levels of physical function. 25, 26 In mouse models, it has been suggested that peripheral monocytes/macrophages infiltrated spinal cords during the course of disease using Ly6C and CD169 as markers for monocytederived macrophages.
18 
Conclusions
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